Drug Profile
EC 372
Alternative Names: EC372Latest Information Update: 28 Nov 2021
Price :
$50
*
At a glance
- Originator Evestra
- Class Antineoplastics
- Mechanism of Action Selective estrogen receptor degraders
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Breast cancer
Most Recent Events
- 28 Nov 2021 No recent reports of development identified for preclinical development in Breast-cancer in USA
- 26 Oct 2017 Preclinical trials in Breast cancer in USA (unspecified route)
- 26 Oct 2017 Pharmacodynamics data from preclinical studies in Breast cancer presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2017 (AACR-NCI-EORTC-2017)